Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

25.27
-0.3800-1.48%
Post-market: 25.610.3400+1.35%17:35 EDT
Volume:590.17K
Turnover:14.99M
Market Cap:2.23B
PE:-5.77
High:25.86
Open:25.68
Low:24.95
Close:25.65
52wk High:47.65
52wk Low:14.53
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.64
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:4.04
PE(LYR):-11.03

Loading ...

Company Profile

Company Name:
Mineralys Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
76
Office Location:
150 N. Radnor Chester Road,Suite F200,Radnor,Pennsylvania,United States
Zip Code:
19087
Fax:
- -
Introduction:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Directors

Name
Position
Glenn Sblendorio
Chairman and Independent Director
Jon Congleton
President, Chief Executive Officer, and Director
Alexander M. Gold
Independent Director
Brian Taylor Slingsby
Independent Director
Daphne Karydas
Independent Director
Derek DiRocco
Independent Director
Srinivas Akkaraju
Independent Director

Shareholders

Name
Position
Jon Congleton
President, Chief Executive Officer, and Director
Adam Levy
Chief Financial Officer and Secretary
David Rodman
Chief Medical Officer
Eric Warren
Chief Commercial Officer